

In The Claims:

1-7 (Canceled).

8 (Currently Amended). A stabilized medicament comprising:

(A) an effervescent system comprising:

(i) a CO₂ donor, and

(ii) an acidic component;

(B) a degradable pharmaceutically active substance, and

(C) at least one ingredient, ~~present in an amount sufficient to stabilize at least one of said CO₂ donor, and said acidic component~~, selected from the group consisting of fusible sugars, sugar alcohols, and sugar substitutes, wherein at least one of said CO₂ donor and said acidic component is dispersed ~~substantially throughout in said ingredient a substrate having said ingredient as a substantial constituent~~, wherein said substrate ingredient and said at least one of said CO₂ donor and said acidic component dispersed therein have a structure formed by melting said substrate ingredient and dispersing said at least one of said CO₂ donor and said acidic component therein and resolidifying said substrate ingredient and at least one of said CO₂ donor and said acidic component, wherein a sufficient amount of said CO₂ donor or said acidic component is dispersed in said ingredient to stabilize at least one of said CO₂ donor, said acidic component, and said degradable pharmaceutically active substance.

9 (Previously Presented). The stabilized medicament of claim 8, wherein said ingredient has a melting point from 30° C to 200° C.

10 (Previously Presented). The stabilized medicament of claim 9, wherein said ingredient has a melting point from 40° C to 160° C.

11 (Currently Amended). A process for producing a stabilized medicament, said stabilized medicament comprising:

(A) an effervescent system comprising:

(i) a CO₂ donor, and

(ii) an acidic component;

(B) a degradable pharmaceutically active substance, and

(C) at least one ingredient selected from the group consisting of fusible sugars, sugar alcohols, and sugar substitutes,

wherein said process comprises the steps of: (a) at least partially melting said ingredient, (b) mixing at least one of said CO₂ donor and said acidic component with said at least partially melted ingredient ~~wherein said ingredient is present in an amount sufficient to stabilize said at least one of said CO₂ donor and said acidic component~~ to form an at least partially molten blend in which said at least one of said CO₂ donor and said acidic component is ~~substantially~~ dispersed, (c) cooling said at least partially molten blend, (d) combining said cooled at least partially molten blend, said pharmaceutically active substance and any remaining portion of said effervescent system and (e) forming said stabilized medicament, wherein said ingredient is present in an amount sufficient to stabilize at least one of said CO₂ donor, said acidic component, and said degradable pharmaceutically active substance.

12 (Currently Amended). The process of claim 11, wherein said step of at least partially melting said ~~ancillary substance~~ ingredient is carried out at a temperature from 30° C to 200° C.

13 (Currently Amended). The process of claim 12, wherein said step of at least partially melting said ~~ancillary substance~~ ingredient is carried out at a temperature from 40° C to 160° C.

14 (Previously Presented). The process of claim 11, where said blend is comminuted after cooling.

15 (Previously Presented). The process of claim 11, wherein said medicament is tabletted.

16 (New). The medicament of claim 8, wherein said degradable pharmaceutically active substance is aspirin.

17 (New). The process of claim 11, wherein said degradable pharmaceutically active substance is aspirin.